Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Incyte Corporation (INCY), Gilead Sciences, Inc. (GILD): Pop-Worthy Data, Incyte, but Let’s See More

Reading between the lines, it appears that Jakafi isn’t extending survival by all that much when you look median survival. It’s possible that there’s a subgroup of the subgroup that responds really well, which drives up the six-month survival but hardly moves the median survival.

That’s potentially still meaningful — most patients with advanced pancreatic cancer live less than a year — but without the full data, it’s just speculation.

The big tell
These questions will eventually be answered, most likely when the full data is presented at a medical meeting or when the protocol for the phase 3 trial is disclosed.

But investors might get an idea of the strength of the data before that from Incyte Corporation (NASDAQ:INCY)’s partner Novartis AG (ADR) (NYSE:NVS), which can opt in to pay for the expanded indication. The pharma will presumably get to see a lot more data than we have in the press release. Novartis opting in would be a good sign that knowledgeable people think the data is strong enough to pursue further.

The article Pop-Worthy Data, Incyte, but Let’s See More originally appeared on Fool.com.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. 

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.